NEW YORK (GenomeWeb News) - Roche NimbleGen said today it has expanded a patent license agreement with Affymetrix to include diagnostic rights to array-based DNA analysis and array-based re-sequencing.
NimbleGen and Affymetrix originally agreed to the patent license, which gave NimbleGen the rights to patents related to the manufacture, use, and sale of nucleic acid microarrays, in October 2006.
When Roche purchased NimbleGen last June for $272 million, the licensing rights were transferred to Roche NimbleGen.
Roche NimbleGen makes high-density arrays of long oligo probes used in studying genomic and epigenomics variation.
Financial terms of the latest agreement were not released.